Therapeutics of Natural and Synthetic Compounds in Protease Induced Cancer presents a detailed discussion on the role of therapeutic and synthetic compounds in proteases and how they have been utilized to develop anticancer drugs, covering both their structure and functions. In addition, the book explores the experimental and theoretical aspects of natural and synthetic compound design based on proteases. Sections bridge the gap between fundamental and translational research, with applications in the biomedical and pharmaceutical industry, making it a thought-provoking read for basic and applied scientists engaged in biomedical research.
In 23 chapters, this book gives both insights on the general aspects of the role of natural and synthetic compounds in cancer therapeutics, in cancer development, treatment, and their use in clinical trails. Given the breadth and depth of information covered in the respective contributions, the book will be immensely useful for researchers in oncology and for those working to identify targets for drug development.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. Dedication - p. va 8. List of contributors - p. xix 9. List of contributors - p. xviia 10. Preface to Volume 1 - p. xxv 11. Preface to Volume 2 - p. xxia 12. Part I: Volume I: Therapeutic aspects of some natural compounds in pro-teases-induced cancer - p. 1 13. Section A: General aspects - p. 3 14. Chapter 1. Role of matrix metalloproteinases in triple negative breast cancer - p. 5 15. Chapter 2. Effects of natural products on proteases associated with cancers - p. 19 16. Chapter 3. The impact of polyphenols on protease regulation in cancer therapy - p. 29 17. Chapter 4. Understanding the role of plant-derived protease-inhibitors in cancer therapy: a therapeutic approach - p. 43 18. Chapter 5. Unveiling phytonutraceuticals as potential photosensitizers in advanced photodynamic cancer therapy - p. 53 19. Section B: Inflammation and immune response - p. 67 20. Chapter 6. Caspase response of inflammasomes in breast cancer - p. 69 21. Chapter 7. Unraveling the role of cysteine cathepsins in tumor microenvironment aiding progression and metastasis of tumor - p. 97 22. Chapter 8. Metalloproteases: the effectors of inflammation in breast cancer progression - p. 117 23. Chapter 9. Proteases in immune response, oncogenesis and beyond - p. 131 24. Chapter 10. Matrix metalloproteases induced inflammation in head and neck squamous cell carcinoma - p. 149 25. Chapter 11. Serine proteases in prostate cancer: unraveling the interplay of inflammation and immune response - p. 169 26. Chapter 12. Dynamics of matrix metalloproteases and serine proteases in colorectal cancer - p. 189 27. Chapter 13. Proteases as key players in metastasis-inflammation and immune response - p. 213 28. Section C: Plant derived compounds in proteases induced cancer - p. 225 29. Chapter 14. Therapeutic aspects of some natural compounds in urokinase plasminogen activator induced cancer - p. 227 30. Chapter 15. From naturally sourced aspartic and metalloproteases inhibitors to therapeutic aspects of skin cancer - p. 243 31. Chapter 16. Role of natural bioactive small molecules as inhibitors for cysteine proteases in cancer - p. 251 32. Chapter 17. Flavonoids as protease inhibitors in cancer chemoprevention - p. 269 33. Chapter 18. Naturally occurring compounds as protease inhibitors for key matrix remodeling enzymes in cancer - p. 287 34. Chapter 19. Advances in plant trypsin/chymotrypsin inhibitors for targeting reproductive cancers - p. 307 35. Chapter 20. Natural compounds as potential cancer therapeutics: a focus on curcumin and resveratrol - p. 323 36. Chapter 21. Autophagy modulation in cancer: the plant alkaloid connection—mechanistic insights and therapeutic strategies - p. 335 37. Chapter 22. Berberine, matrix metalloproteinases, and cancer: a brief overview - p. 347 38. Indian gooseberry (Emblica officinalis) and its phytochemicals as modulators of matrix metalloproteinase in skin - p. 369 39. Chapter 24. Plant-derived natural protease inhibitors against cancer: casting about for newer cancer chemopreventive and chemotherapeutic agents - p. 381 40. Chapter 25. Compounds of plant origin as therapeutics for serine protease implicated in colorectal cancer - p. 395 41. Chapter 26. Plant peptides and proteins as protease inhibitors in breast cancer therapy - p. 415 42. Chapter 27. Exploring the potentials of genistein, lycopene, and ellagic acid as protease inhibitors in cancer therapeutics - p. 433 43. Chapter 28. Modulation of proteases in liver cancer by quercetin: a therapeutic perspective - p. 451 44. Withania somnifera Dunal (Ashwagandha) and its phytochemicals as matrix metalloproteinases inhibitors in cancer - p. 469 45. Chapter 30. Natural compounds as inhibitors of the matrix metalloproteinase expression and enzymatic activity: the past, present, and future - p. 479 46. Chapter 31. A comprehensive overview of epigallocatechin gallate and its role in human osteosarcoma inhibition - p. 513 47. Chapter 32. Role of some naturally derived compounds in the therapeutics of matrix metalloprotease-2 and membrane type-1-matrix metalloproteinase induced cancer - p. 531 48. Chapter 33. Role of caspases in colorectal cancer therapy by curcumin - p. 559 49. Section D: Animal derived compounds in proteases induced cancer - p. 583 50. Chapter 34. Dietary proteases and their connection to cancer - p. 585 51. Chapter 35. Snake venom proteases as potential cancer therapeutics - p. 603 52. Chapter 36. Therapeutics of bortezomib, carfilzomib, and ixazomib in proteases-induced cancer - p. 623 53. Part II: Volume II: Therapeutic aspects of some synthetic compounds - p. 1a 54. Section A: General Aspects - p. 3a 55. Chapter 1. Role of synthetic protease inhibitors in lung cancer treatment - p. 5a 56. Chapter 2. Matrix metalloproteases in head and neck cancers - p. 15a 57. Chapter 3. Role of proteases and cytokines in cancer growth - p. 29a 58. Chapter 4. Protease inhibitors handshake with cell fate: targeting pancreatic cancer - p. 41a 59. Chapter 5. Insights into the potential significance of cysteine proteinase in lung cancer - p. 67a 60. Chapter 6. Novel therapeutic strategies using synthetic compounds to target and treat protease-induced cancer - p. 79a 61. Chapter 7. Role of proteases in tumor progression and their significance as potential therapeutic targets - p. 89a 62. Section B: Proteases in cancer diagnosis - p. 97a 63. Chapter 8. Targeting matrix metalloproteinases-2 and -9 for breast cancer treatment - p. 99a 64. Chapter 9. Serine proteases as targets for cancer treatment - p. 113a 65. Chapter 10. Cathepsins as an important pharmacological target for multiple cancer types - p. 129a 66. Chapter 11. Unraveling the potential of high-temperature requirement A serine protease in anticancer strategies - p. 141a 67. Chapter 12. Proteasome-targeted therapies in cancer - p. 157a 68. Chapter 13. Protease and circRNA-targeted drug therapy in gastric cancer - p. 177a 69. Section C: Cutting edge technologies - p. 197a 70. Chapter 14. Cutting edge therapeutics targeting matrix metalloproteases for glioma - p. 199a 71. Chapter 15. The role of urokinase type plasminogen activator in colorectal cancer: innovative therapies and cutting-edge technologies - p. 207a 72. Chapter 16. Different ways of identification and characterization of proteases in cancer - p. 221a 73. Chapter 17. Bioinformatics and system biology approach for proteases induced cancer drug designing - p. 235a 74. Chapter 18. CyberKnife technology and cancer management - p. 243a 75. Chapter 19. Impact of epigenetic techniques and noncoding RNAs in neurological cancer - p. 259a 76. Section D: Synthetic compounds in proteases induced cancer - p. 279a 77. Chapter 20. Therapeutic aspects of some synthetic compounds in urokinase plasminogen activator-induced cancer - p. 281a 78. Chapter 21. Metalloproteinases in the crosshairs: protease inhibitors and their role in cancer suppression - p. 303a 79. Chapter 22. Mechanism of action and application of proteasome inhibitor bortezomib in the treatment of multiple myeloma - p. 321a 80. Chapter 23. Unveiling the therapeutic potential of synthetic protease inhibitors: targeting the proteosome in colorectal cancer - p. 335a 81. Chapter 24. Role of boron containing synthetic compounds as serine proteases inhibitors in prostate cancer - p. 353a 82. Chapter 25. Role of some synthetic compounds in matrix metalloproteases-induced cancer - p. 361a 83. Section E: Protease inhibitors in clinical trials - p. 383a 84. Chapter 26. Inhibitors of matrix metalloproteinases in clinical trials - p. 385a 85. Chapter 27. Breast cancer therapeutics by protease inhibitors - p. 419a 86. Chapter 28. Clinical trials on the efficacy of anticancer protease inhibitors on breast, prostate, lungs - p. 439a 87. Chapter 29. Clinical trials of nelfinavir protease inhibitor in cancer treatment - p. 455a 88. Index - p. 641 89. Index - p. 473a
Therapeutics of Natural and Synthetic Compounds in Protease Induced Cancer presents a detailed discussion on the role of therapeutic and synthetic compounds in proteases and how they have been utilized to develop anticancer drugs, covering both their structure and functions. In addition, the book explores the experimental and theoretical aspects of natural and synthetic compound design based on proteases. Sections bridge the gap between fundamental and translational research, with applications in the biomedical and pharmaceutical industry, making it a thought-provoking read for basic and applied scientists engaged in biomedical research.
In 23 chapters, this book gives both insights on the general aspects of the role of natural and synthetic compounds in cancer therapeutics, in cancer development, treatment, and their use in clinical trails. Given the breadth and depth of information covered in the respective contributions, the book will be immensely useful for researchers in oncology and for those working to identify targets for drug development.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. Dedication - p. va 8. List of contributors - p. xix 9. List of contributors - p. xviia 10. Preface to Volume 1 - p. xxv 11. Preface to Volume 2 - p. xxia 12. Part I: Volume I: Therapeutic aspects of some natural compounds in pro-teases-induced cancer - p. 1 13. Section A: General aspects - p. 3 14. Chapter 1. Role of matrix metalloproteinases in triple negative breast cancer - p. 5 15. Chapter 2. Effects of natural products on proteases associated with cancers - p. 19 16. Chapter 3. The impact of polyphenols on protease regulation in cancer therapy - p. 29 17. Chapter 4. Understanding the role of plant-derived protease-inhibitors in cancer therapy: a therapeutic approach - p. 43 18. Chapter 5. Unveiling phytonutraceuticals as potential photosensitizers in advanced photodynamic cancer therapy - p. 53 19. Section B: Inflammation and immune response - p. 67 20. Chapter 6. Caspase response of inflammasomes in breast cancer - p. 69 21. Chapter 7. Unraveling the role of cysteine cathepsins in tumor microenvironment aiding progression and metastasis of tumor - p. 97 22. Chapter 8. Metalloproteases: the effectors of inflammation in breast cancer progression - p. 117 23. Chapter 9. Proteases in immune response, oncogenesis and beyond - p. 131 24. Chapter 10. Matrix metalloproteases induced inflammation in head and neck squamous cell carcinoma - p. 149 25. Chapter 11. Serine proteases in prostate cancer: unraveling the interplay of inflammation and immune response - p. 169 26. Chapter 12. Dynamics of matrix metalloproteases and serine proteases in colorectal cancer - p. 189 27. Chapter 13. Proteases as key players in metastasis-inflammation and immune response - p. 213 28. Section C: Plant derived compounds in proteases induced cancer - p. 225 29. Chapter 14. Therapeutic aspects of some natural compounds in urokinase plasminogen activator induced cancer - p. 227 30. Chapter 15. From naturally sourced aspartic and metalloproteases inhibitors to therapeutic aspects of skin cancer - p. 243 31. Chapter 16. Role of natural bioactive small molecules as inhibitors for cysteine proteases in cancer - p. 251 32. Chapter 17. Flavonoids as protease inhibitors in cancer chemoprevention - p. 269 33. Chapter 18. Naturally occurring compounds as protease inhibitors for key matrix remodeling enzymes in cancer - p. 287 34. Chapter 19. Advances in plant trypsin/chymotrypsin inhibitors for targeting reproductive cancers - p. 307 35. Chapter 20. Natural compounds as potential cancer therapeutics: a focus on curcumin and resveratrol - p. 323 36. Chapter 21. Autophagy modulation in cancer: the plant alkaloid connection—mechanistic insights and therapeutic strategies - p. 335 37. Chapter 22. Berberine, matrix metalloproteinases, and cancer: a brief overview - p. 347 38. Indian gooseberry (Emblica officinalis) and its phytochemicals as modulators of matrix metalloproteinase in skin - p. 369 39. Chapter 24. Plant-derived natural protease inhibitors against cancer: casting about for newer cancer chemopreventive and chemotherapeutic agents - p. 381 40. Chapter 25. Compounds of plant origin as therapeutics for serine protease implicated in colorectal cancer - p. 395 41. Chapter 26. Plant peptides and proteins as protease inhibitors in breast cancer therapy - p. 415 42. Chapter 27. Exploring the potentials of genistein, lycopene, and ellagic acid as protease inhibitors in cancer therapeutics - p. 433 43. Chapter 28. Modulation of proteases in liver cancer by quercetin: a therapeutic perspective - p. 451 44. Withania somnifera Dunal (Ashwagandha) and its phytochemicals as matrix metalloproteinases inhibitors in cancer - p. 469 45. Chapter 30. Natural compounds as inhibitors of the matrix metalloproteinase expression and enzymatic activity: the past, present, and future - p. 479 46. Chapter 31. A comprehensive overview of epigallocatechin gallate and its role in human osteosarcoma inhibition - p. 513 47. Chapter 32. Role of some naturally derived compounds in the therapeutics of matrix metalloprotease-2 and membrane type-1-matrix metalloproteinase induced cancer - p. 531 48. Chapter 33. Role of caspases in colorectal cancer therapy by curcumin - p. 559 49. Section D: Animal derived compounds in proteases induced cancer - p. 583 50. Chapter 34. Dietary proteases and their connection to cancer - p. 585 51. Chapter 35. Snake venom proteases as potential cancer therapeutics - p. 603 52. Chapter 36. Therapeutics of bortezomib, carfilzomib, and ixazomib in proteases-induced cancer - p. 623 53. Part II: Volume II: Therapeutic aspects of some synthetic compounds - p. 1a 54. Section A: General Aspects - p. 3a 55. Chapter 1. Role of synthetic protease inhibitors in lung cancer treatment - p. 5a 56. Chapter 2. Matrix metalloproteases in head and neck cancers - p. 15a 57. Chapter 3. Role of proteases and cytokines in cancer growth - p. 29a 58. Chapter 4. Protease inhibitors handshake with cell fate: targeting pancreatic cancer - p. 41a 59. Chapter 5. Insights into the potential significance of cysteine proteinase in lung cancer - p. 67a 60. Chapter 6. Novel therapeutic strategies using synthetic compounds to target and treat protease-induced cancer - p. 79a 61. Chapter 7. Role of proteases in tumor progression and their significance as potential therapeutic targets - p. 89a 62. Section B: Proteases in cancer diagnosis - p. 97a 63. Chapter 8. Targeting matrix metalloproteinases-2 and -9 for breast cancer treatment - p. 99a 64. Chapter 9. Serine proteases as targets for cancer treatment - p. 113a 65. Chapter 10. Cathepsins as an important pharmacological target for multiple cancer types - p. 129a 66. Chapter 11. Unraveling the potential of high-temperature requirement A serine protease in anticancer strategies - p. 141a 67. Chapter 12. Proteasome-targeted therapies in cancer - p. 157a 68. Chapter 13. Protease and circRNA-targeted drug therapy in gastric cancer - p. 177a 69. Section C: Cutting edge technologies - p. 197a 70. Chapter 14. Cutting edge therapeutics targeting matrix metalloproteases for glioma - p. 199a 71. Chapter 15. The role of urokinase type plasminogen activator in colorectal cancer: innovative therapies and cutting-edge technologies - p. 207a 72. Chapter 16. Different ways of identification and characterization of proteases in cancer - p. 221a 73. Chapter 17. Bioinformatics and system biology approach for proteases induced cancer drug designing - p. 235a 74. Chapter 18. CyberKnife technology and cancer management - p. 243a 75. Chapter 19. Impact of epigenetic techniques and noncoding RNAs in neurological cancer - p. 259a 76. Section D: Synthetic compounds in proteases induced cancer - p. 279a 77. Chapter 20. Therapeutic aspects of some synthetic compounds in urokinase plasminogen activator-induced cancer - p. 281a 78. Chapter 21. Metalloproteinases in the crosshairs: protease inhibitors and their role in cancer suppression - p. 303a 79. Chapter 22. Mechanism of action and application of proteasome inhibitor bortezomib in the treatment of multiple myeloma - p. 321a 80. Chapter 23. Unveiling the therapeutic potential of synthetic protease inhibitors: targeting the proteosome in colorectal cancer - p. 335a 81. Chapter 24. Role of boron containing synthetic compounds as serine proteases inhibitors in prostate cancer - p. 353a 82. Chapter 25. Role of some synthetic compounds in matrix metalloproteases-induced cancer - p. 361a 83. Section E: Protease inhibitors in clinical trials - p. 383a 84. Chapter 26. Inhibitors of matrix metalloproteinases in clinical trials - p. 385a 85. Chapter 27. Breast cancer therapeutics by protease inhibitors - p. 419a 86. Chapter 28. Clinical trials on the efficacy of anticancer protease inhibitors on breast, prostate, lungs - p. 439a 87. Chapter 29. Clinical trials of nelfinavir protease inhibitor in cancer treatment - p. 455a 88. Index - p. 641 89. Index - p. 473a
